
Loris BAGGETTO
Equipe : Vecteurs colloïdaux et ingénierie thérapeutique ciblée
Courriel : loris.baggetto@ibcp.fr
Téléphone : +33(0)4-72-72-26-35
Statut : Directeur de recherches
30 publications au total. Seules les 5 dernières années sont affichées
2014
30. [Application of gene therapy to oncologic ophthalmology].
Philiponnet A, Grange Jd, Baggetto Lg
(2014) J Fr Ophtalmol 37 :155-65

2008
29. Regulation of brain endothelial cells migration and angiogenesis by P-glycoprotein/caveolin-1 interaction.
Barakat S, Turcotte S, Demeule M, Lachambre Mp, Regina A, Baggetto Lg, Beliveau R
(2008) Biochem Biophys Res Commun 372 :440-6

2007
28. Survival after primary enucleation for choroidal melanoma: changes induced by the introduction of conservative therapies.
Gambrelle J, Grange Jd, Devouassoux Shisheboran M, Rivoire M, Baggetto Lg, Jean-louis B, Fleury J, Kodjikian L
(2007) Graefes Arch Clin Exp Ophthalmol 245 :657-63

2005
27. Major cytogenetic aberrations and typical multidrug resistance phenotype of uveal melanoma: current views and new therapeutic prospects.
Baggetto Lg, Gambrelle J, Dayan G, Labialle S, Barakat S, Michaud M, Grange Jd, Gayet L
(2005) Cancer Treat Rev 31 :361-79

26. Multidrug-resistant cancer cells contain two populations of P-glycoprotein with differently stimulated P-gp ATPase activities: evidence from atomic force microscopy and biochemical analysis.
Barakat S, Gayet L, Dayan G, Labialle S, Lazar A, Oleinikov V, Coleman Aw, Baggetto Lg
(2005) Biochem J 388 :563-71

25. Uveal melanoma in an 18-year-old African black man.
Gambrelle J, Dayan G, Baggetto Lg, Devouassoux-shisheboran M, Salle M, Labialle S, Gayet L, Barakat S, Kodjikian L, Grange Jd
(2005) Acta Ophthalmol Scand 83 :134-6

24. [Multidrug resistance in uveal melanoma].
Gambrelle J, Labialle S, Dayan G, Gayet L, Barakat S, Michaud M, Grange Jd, Baggetto Lg
(2005) J Fr Ophtalmol 28 :652-9

23. Control of P-glycoprotein activity by membrane cholesterol amounts and their relation to multidrug resistance in human CEM leukemia cells.
Gayet L, Dayan G, Barakat S, Labialle S, Michaud M, Cogne S, Mazane A, Coleman Aw, Rigal D, Baggetto Lg
(2005) Biochemistry 44 :4499-509

22. Characterization of the typical multidrug resistance profile in human uveal melanoma cell lines and in mouse liver metastasis derivatives.
Labialle S, Dayan G, Gambrelle J, Gayet L, Barakat S, Devouassoux-shisheboran M, Bernaud J, Rigal D, Grange Jd, Baggetto Lg
(2005) Melanoma Res 15 :257-66

21. Gene therapy of the typical multidrug resistance phenotype of cancers: a new hope?
Labialle S, Dayan G, Michaud M, Barakat S, Rigal D, Baggetto Lg
(2005) Semin Oncol 32 :583-90

2004
20. [Toward monosomy 3 as the main prognosis factor of uveal melanoma: current cytogenetic data].
Gambrelle J, Labialle S, Dayan G, Gayet L, Barakat S, Grange Jd, Baggetto Lg
(2004) J Fr Ophtalmol 27 :1061-7

19. New invMED1 element cis-activates human multidrug-related MDR1 and MVP genes, involving the LRP130 protein.
Labialle S, Dayan G, Gayet L, Rigal D, Gambrelle J, Baggetto Lg
(2004) Nucleic Acids Res 32 :3864-76

2002
18. Transcriptional regulation of the human MDR1 gene at the level of the inverted MED-1 promoter region.
Labialle S, Gayet L, Marthinet E, Rigal D, Baggetto Lg
(2002) Ann N Y Acad Sci 973 :468-71

17. Transcriptional regulators of the human multidrug resistance 1 gene: recent views.
Labialle S, Gayet L, Marthinet E, Rigal D, Baggetto Lg
(2002) Biochem Pharmacol 64 :943-8

16. Effects of P-glycoprotein on the properties of lipid monolayers probed by Langmuir-Blodgett technique
Zaitsev Sy, Volchenkova Ta, Ustinova Oa, Koshtigo Tv, Baggetto Lg, Fleury F, Madoulet C, Nabiev Ir, Oleinikov Va
(2002) Biofizika 47 :1073-1079
2000
15. Modulation of the typical multidrug resistance phenotype by targeting the MED-1 region of human MDR1 promoter.
Marthinet E, Divita G, Bernaud J, Rigal D, Baggetto Lg
(2000) Gene Ther 7 :1224-33

1998
14. In vitro and in vivo reversal of cancer cell multidrug resistance by the semi-synthetic antibiotic tiamulin.
Baggetto Lg, Dong M, Bernaud J, Espinosa L, Rigal D, Bonvallet R, Marthinet E
(1998) Biochem Pharmacol 56 :1219-28

13. Secondary structure of P-glycoprotein investigated by circular dichroism and amino acid sequence analysis.
Dong M, Ladaviere L, Penin F, Deleage G, Baggetto Lg
(1998) Biochim Biophys Acta 1371 :317-34

1997
12. Biochemical, genetic, and metabolic adaptations of tumor cells that express the typical multidrug-resistance phenotype. Reversion by new therapies.
Baggetto Lg
(1997) J Bioenerg Biomembr 29 :401-13

11. Non P-glycoprotein novel proteins involved in human cancer multidrug resistance.
Baggetto Lg
(1997) Bull Cancer 84 :385-90

1996
10. Efficient purification and reconstitution of P-glycoprotein for functional and structural studies.
Dong M, Penin F, Baggetto Lg
(1996) J Biol Chem 271 :28875-83

1992
9. Role of mitochondria in carcinogenesis.
Baggetto Lg
(1992) Eur J Cancer 29A :156-9

8. Low mitochondrial proton leak due to high membrane cholesterol content and cytosolic creatine kinase as two features of the deviant bioenergetics of Ehrlich and AS30-D tumor cells.
Baggetto Lg, Clottes E, Vial C
(1992) Cancer Res 52 :4935-41

1991
7. Identification of F0 subunits in the rat liver mitochondrial F0F1-ATP synthase.
Cretin F, Baggetto Lg, Denoroy L, Godinot C
(1991) Biochim Biophys Acta 1058 :141-6

1990
6. Role of acetoin on the regulation of intermediate metabolism of Ehrlich ascites tumor mitochondria: its contribution to membrane cholesterol enrichment modifying passive proton permeability.
Baggetto Lg, Testa-parussini R
(1990) Arch Biochem Biophys 283 :241-8

1987
5. Formation and utilization of acetoin, an unusual product of pyruvate metabolism by Ehrlich and AS30-D tumor mitochondria.
Baggetto Lg, Lehninger Al
(1987) J Biol Chem 262 :9535-41

4. Isolated tumoral pyruvate dehydrogenase can synthesize acetoin which inhibits pyruvate oxidation as well as other aldehydes.
Baggetto Lg, Lehninger Al
(1987) Biochem Biophys Res Commun 145 :153-9

1986
3. Reversal of glucose-induced inhibition of newborn rat liver mitochondrial maturation by administration of alkylxanthines at birth.
Comte J, Meister R, Baggetto Lg, Godinot C, Gautheron Dc
(1986) Biochem Pharmacol 35 :2411-6

1984
2. Effects of ATP on various steps controlling the rate of oxidative phosphorylation in newborn rat liver mitochondria.
Baggetto L, Gautheron Dc, Godinot C
(1984) Arch Biochem Biophys 232 :670-8

1983
1. High phosphate requirement for oxidative phosphorylation and low affinity for phosphate transport in newborn rat liver mitochondria.
Baggetto L, Comte J, Meister R, Godinot C
(1983) Biochimie 65 :685-90
